Nabi Biopharmaceuticals has a pipeline of biopharmaceutical products under development. These research and development pipeline products consist of novel vaccines in various stages of development to prevent and/or treat nicotine addition and Gram-positive bacterial infections. The lead product, NicVAX for nicotine addiction , is currently being studied in Phase III clinical trials. These pipeline products represent an opportunity to help address the significant medical needs of millions of people around the world.